Identification of pyrrolo[2,3-d]pyrimidine-based dual MERTK and FLT3 inhibitor: Hit-to-lead, machine learning, modeling, synthesis, and biological evaluation
Year: 2026
Type: article
Abstract: value of 7.50 nM). Furthermore, compound 31l displayed a favorable metabolic stability profile in both human and mouse liver microsome screens and an oral bioavailability of 56%. This finding suggests that lead compound 31l is a promising tool for further optimization and development as a potential MERTK/FLT3 dual inhibitor anti-AML drug candidate.
Authors: Abdellah Yamani, Paweł Maliszewski, Natalia Piórkowska, Patrycja Olejkowska-Podgórska, Wojciech Pietruś, Mario Luigi Naitana, Agata Mitkowska, Artur Łaszek, Delfina Popiel, Agata Mikołajczyk, Tomasz Kornatowski, Kinga Jastrzębska, Filip Mituła, Jakub Dominowski, Artur Janusz, Michał Górka, Joanna Hucz-Kalitowska, Małgorzata Teska-Kamińska, Aleksandra Stańczak, Monika Delis, Damian Smuga, Jerzy Pieczykolan, Krzysztof Dubiel, Maciej Wieczorek
Institution: Celon Pharma (Poland)
Language: English
Subfield: Organic Chemistry
Field: Chemistry
Domain: Physical Sciences
Open Access status: gold
Estimated APC paid: $3,070
Funder: Narodowe Centrum Badań i Rozwoju
Award: G7307576261
OpenAlex ID: W7126119785